These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. van der Lubbe PA; Reiter C; Miltenburg AM; Krüger K; de Ruyter AN; Rieber EP; Bijl JA; Riethmüller G; Breedveld FC Scand J Immunol; 1994 Mar; 39(3):286-94. PubMed ID: 8128188 [TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Moreland LW; Pratt PW; Bucy RP; Jackson BS; Feldman JW; Koopman WJ Arthritis Rheum; 1994 Jun; 37(6):834-8. PubMed ID: 7911664 [TBL] [Abstract][Full Text] [Related]
6. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. van der Lubbe PA; Reiter C; Breedveld FC; Krüger K; Schattenkirchner M; Sanders ME; Riethmüller G Arthritis Rheum; 1993 Oct; 36(10):1375-9. PubMed ID: 8216397 [TBL] [Abstract][Full Text] [Related]
7. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis. van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303 [TBL] [Abstract][Full Text] [Related]
8. In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Jonker M; Slingerland W; Treacy G; van Eerd P; Pak KY; Wilson E; Tam S; Bakker K; Lobuglio AF; Rieber P Clin Exp Immunol; 1993 Sep; 93(3):301-7. PubMed ID: 8103714 [TBL] [Abstract][Full Text] [Related]
9. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Choy EH; Pitzalis C; Cauli A; Bijl JA; Schantz A; Woody J; Kingsley GH; Panayi GS Arthritis Rheum; 1996 Jan; 39(1):52-6. PubMed ID: 8546738 [TBL] [Abstract][Full Text] [Related]
10. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Tak PP; van der Lubbe PA; Cauli A; Daha MR; Smeets TJ; Kluin PM; Meinders AE; Yanni G; Panayi GS; Breedveld FC Arthritis Rheum; 1995 Oct; 38(10):1457-65. PubMed ID: 7575695 [TBL] [Abstract][Full Text] [Related]
11. Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. Choy EH; Adjaye J; Forrest L; Kingsley GH; Panayi GS Eur J Immunol; 1993 Oct; 23(10):2676-81. PubMed ID: 8104799 [TBL] [Abstract][Full Text] [Related]
12. Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Horneff G; Emmrich F; Burmester GR Br J Rheumatol; 1993 Jun; 32 Suppl 4():39-47. PubMed ID: 8099518 [TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Choy EH; Chikanza IC; Kingsley GH; Corrigall V; Panayi GS Scand J Immunol; 1992 Aug; 36(2):291-8. PubMed ID: 1354392 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806 [TBL] [Abstract][Full Text] [Related]
16. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody. Dalesandro MR; Pak KY; Tam S; Wilson E; Looney JE; Knight DM; Ghrayeb J; Reiter C; Rieber EP; Riethmuller G Int Immunol; 1993 Mar; 5(3):283-91. PubMed ID: 8466865 [TBL] [Abstract][Full Text] [Related]
17. Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5). Racadot E; Wijdenes J; Wendling D Clin Exp Rheumatol; 1992; 10(4):365-74. PubMed ID: 1356679 [TBL] [Abstract][Full Text] [Related]
18. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. Yocum DE; Solinger AM; Tesser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dallaire B; Shen CD; Lipani J J Rheumatol; 1998 Jul; 25(7):1257-62. PubMed ID: 9676753 [TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Horneff G; Burmester GR; Emmrich F; Kalden JR Arthritis Rheum; 1991 Feb; 34(2):129-40. PubMed ID: 1994909 [TBL] [Abstract][Full Text] [Related]
20. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]